VISTARA BIOSCIENCE

Vistara Bioscience is a biotechnology startup that focuses on developing proteomics tools for drug discovery research, particularly in the field of Targeted Protein Degradation (TPD) and other therapeutic modalities. The company's TRIFECTA strategy involves a combination of ubiquitomics, compound screening, and protein disruption processes with clinical applications in Oncology, Inflammation, and Neurodegeneration disease areas. Recent clinical outcomes in TPD have highlighted the complexity involved in finding effective solutions, emphasizing the need for detailed information about the clinical target's proteostasis mechanisms. Vistara Bioscience's global ubiquitome scanning technologies aim to identify similarities and differences between samples, providing contextual information about target protein's proteostasis, including protein networks, accessory factors, pathway components, and compound-induced changes of proteins in collaboration with proteins of clinical interest. By integrating their processes, design tools, and informatics, Vistara Bioscience aims to develop tailored TPD solutions. Additionally, the identified networks serve as biomarker panels to guide the drug discovery process and may suggest combinatorial targets or new ones. Founded in 2016, Vistara Bioscience operates within the Big Data, Biotechnology, and IT industries. As of now, there is no available information about the company's last investment or investors.